Pfizer temporarily closed a cancer drug factory in India, and the facility is not expected to reopen for up to two years. The shutdown is already contributing to cancer drug shortages, with the report citing monsoon-related disruption as part of the backdrop. The event adds to ongoing supply-chain fragility risks for oncology therapies, particularly when capacity is concentrated and recovery timelines stretch. For industry stakeholders—pharma manufacturers, distributors, and procurement teams—the immediate focus shifts to allocation strategies, alternative sourcing, and continuity planning. The industrial takeaway is that operational downtime can quickly become a clinical access issue, and shortage mitigation must be treated as a core part of manufacturing risk management, not a reactive process.